VectivBio (VECT) Competitors $16.85 0.00 (0.00%) As of 04/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VECT vs. RXRX, AMRX, VCEL, DNLI, BHVN, MIRM, TARS, BLTE, SDGR, and MTSRShould you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include Recursion Pharmaceuticals (RXRX), Amneal Pharmaceuticals (AMRX), Vericel (VCEL), Denali Therapeutics (DNLI), Biohaven (BHVN), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Belite Bio (BLTE), Schrödinger (SDGR), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. VectivBio vs. Recursion Pharmaceuticals Amneal Pharmaceuticals Vericel Denali Therapeutics Biohaven Mirum Pharmaceuticals Tarsus Pharmaceuticals Belite Bio Schrödinger Metsera VectivBio (NASDAQ:VECT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk. Do insiders and institutionals have more ownership in VECT or RXRX? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 9.7% of VectivBio shares are owned by insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend VECT or RXRX? Recursion Pharmaceuticals has a consensus target price of $8.20, indicating a potential upside of 42.61%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community prefer VECT or RXRX? Recursion Pharmaceuticals received 21 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 55.36% of users gave Recursion Pharmaceuticals an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformVectivBioOutperform Votes1043.48% Underperform Votes1356.52% Recursion PharmaceuticalsOutperform Votes3155.36% Underperform Votes2544.64% Is VECT or RXRX more profitable? VectivBio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. VectivBio's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VectivBioN/A N/A N/A Recursion Pharmaceuticals -579.52%-76.56%-55.68% Which has more volatility & risk, VECT or RXRX? VectivBio has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Does the media refer more to VECT or RXRX? In the previous week, Recursion Pharmaceuticals had 18 more articles in the media than VectivBio. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 0 mentions for VectivBio. Recursion Pharmaceuticals' average media sentiment score of 0.84 beat VectivBio's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment VectivBio Neutral Recursion Pharmaceuticals Positive Which has stronger valuation & earnings, VECT or RXRX? VectivBio has higher earnings, but lower revenue than Recursion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVectivBio$27.34M20.97-$93.74MN/AN/ARecursion Pharmaceuticals$58.49M39.52-$328.07M-$1.66-3.46 SummaryRecursion Pharmaceuticals beats VectivBio on 12 of the 16 factors compared between the two stocks. Get VectivBio News Delivered to You Automatically Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VECT vs. The Competition Export to ExcelMetricVectivBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.24M$2.93B$5.41B$7.70BDividend YieldN/A1.91%5.44%4.33%P/E RatioN/A30.4322.1818.31Price / Sales20.97478.52397.31107.09Price / CashN/A168.6838.2034.62Price / BookN/A3.786.834.25Net Income-$93.74M-$72.06M$3.20B$247.51M7 Day PerformanceN/A11.17%5.77%6.86%1 Month PerformanceN/A-4.87%-4.32%-2.95%1 Year PerformanceN/A-18.74%17.88%5.17% VectivBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeRXRXRecursion Pharmaceuticals2.3762 of 5 stars$5.64+2.4%$8.20+45.4%-27.6%$2.27B$58.49M-3.69400AMRXAmneal Pharmaceuticals3.063 of 5 stars$7.17-0.6%$10.80+50.6%+22.6%$2.22B$2.79B-10.547,600Positive NewsGap UpVCELVericel2.7057 of 5 stars$42.01+1.9%$60.86+44.9%-10.9%$2.11B$237.22M700.28300Positive NewsDNLIDenali Therapeutics4.0931 of 5 stars$13.17-0.8%$37.57+185.3%-0.4%$1.91B$330.53M-4.77430News CoveragePositive NewsBHVNBiohaven3.7083 of 5 stars$18.56+0.3%$62.77+238.1%-39.5%$1.89BN/A-1.99239Options VolumeGap UpMIRMMirum Pharmaceuticals3.9445 of 5 stars$38.63-2.4%$58.20+50.7%+68.5%$1.89B$336.89M-19.12140News CoveragePositive NewsTARSTarsus Pharmaceuticals2.1676 of 5 stars$49.12+0.8%$63.67+29.6%+52.5%$1.89B$182.95M-12.8950News CoveragePositive NewsBLTEBelite Bio2.6309 of 5 stars$58.88+0.5%$96.67+64.2%+59.9%$1.87BN/A-53.0410SDGRSchrödinger2.5447 of 5 stars$25.59-3.6%$32.29+26.2%+8.7%$1.87B$207.54M-10.94790Upcoming EarningsHigh Trading VolumeMTSRMetseraN/A$17.16-5.6%$47.00+173.9%N/A$1.80BN/A0.0081High Trading Volume Related Companies and Tools Related Companies RXRX Alternatives AMRX Alternatives VCEL Alternatives DNLI Alternatives BHVN Alternatives MIRM Alternatives TARS Alternatives BLTE Alternatives SDGR Alternatives MTSR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VECT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VECT Stock Free VECT Stock Alerts